慢性淋巴细胞白血病的治疗进展:重点关注分子致病,向疗法和支持性护理
1Houston Methodist West Hospital, Houston, TX, USA.
概括
向治疗,包括布鲁顿的氨酸激酶抑制剂 (BTKis) 和B细胞白血病/淋巴瘤-2抑制剂 (BCL-2is),改善了慢性淋巴细胞白血病 (CLL) 的治疗结果. 新型药物和支持性护理策略正在推进治疗选择.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性淋巴细胞白血病 (CLL) 是老年人常见的B细胞瘤.
- 结核性淋巴瘤的发病包括复杂的分子事件,包括异常信号传递,受损的亡和微环境相互作用.
- 传统的化学免疫疗法已经被有针对性的口服疗法所超越.
研究的目的:
- 评估目前监管部门批准的CLL的向治疗方法.
- 讨论CLL的分子病原体及其治疗含义.
- 在CLL管理中审查新的向疗法和支持性护理策略.
主要方法:
- 对CLL的向治疗方法的当前文献的综述.
- 对CLL分子病原和治疗点的分析.
- 已批准的口服向疗法的摘要,包括BTKis和BCL-2is.
主要成果:
- 口服向疗法,如布鲁顿的氨酸激酶抑制剂 (BTKis) 和B细胞白血病/淋巴瘤-2抑制剂 (BCL-2is),改善了CLL的生存率.
- 这些药物可以单独或组合用于未经治疗的和复发/耐药的CLL.
- 新兴疗法包括新型BTKis,BTK降解剂和新型BCL-2is.
结论:
- 对CLL的治疗正在发展,选择基于患者特定的因素.
- 新型疗法旨在克服治疗耐药性并优化支持性护理.
- 药剂师在促进CLL治疗和确保患者安全方面发挥着关键作用.
关键词:
这是一个calabrutinib.慢性淋巴细胞白血病 慢性淋巴细胞白血病伊布鲁丁尼布可以.皮尔托布鲁丁尼比 (Pirtobrutinib) 是一种蛋白质.维尼托克拉克斯 (Venetoclax) 是一个赞努布鲁丁尼布 (Zanubrutinib) 是一种药物.更多相关视频
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
14.8K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:27Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
01:27Cytotoxic T Cells-mediated Immune Response
823
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
823